Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection
暂无分享,去创建一个
[1] F. McCormick,et al. Cancer Specific Viruses and the Development of ONYX-015 , 2003, Cancer biology & therapy.
[2] R. May,et al. Infection dynamics on scale-free networks. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.
[3] J. Bell,et al. Getting oncolytic virus therapies off the ground. , 2003, Cancer cell.
[4] H. McCallum,et al. How should pathogen transmission be modelled? , 2001, Trends in ecology & evolution.
[5] A. Barabasi,et al. Halting viruses in scale-free networks. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.
[6] Hyunsuk Shim,et al. Cancer scene investigation: how a cold virus became a tumor killer. , 2005, Future oncology.
[7] Eugene V Koonin,et al. Mathematical modeling of tumor therapy with oncolytic viruses: Regimes with complete tumor elimination within the framework of deterministic models , 2006, Biology Direct.
[8] R. Martuza,et al. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. , 1999, Neoplasia.
[9] M. Begon,et al. Transmission dynamics of a zoonotic pathogen within and between wildlife host species , 1999, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[10] C. O'Shea,et al. Viruses – seeking and destroying the tumor program , 2005, Oncogene.
[11] Nicola Bellomo,et al. A Survey of Models for Tumor-Immune System Dynamics , 1996 .
[12] S. Russell,et al. History of oncolytic viruses: genesis to genetic engineering. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] A. J. Hall. Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .
[14] W. Rom,et al. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. , 2001, Human gene therapy.
[15] M. Roberts,et al. Naturally oncolytic viruses. , 2006, Current opinion in molecular therapeutics.
[16] Frank McCormick,et al. Future prospects for oncolytic therapy , 2005, Oncogene.
[17] R. Martuza,et al. Oncolytic viral therapies – the clinical experience , 2005, Oncogene.
[18] A. Barbour,et al. Epidemics and random graphs , 1990 .
[19] Duncan J. Watts,et al. Collective dynamics of ‘small-world’ networks , 1998, Nature.
[20] M. Newman. Spread of epidemic disease on networks. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.
[21] J. Bell,et al. Oncolytic viruses: what's next? , 2007, Current cancer drug targets.
[22] J. Bell,et al. Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.
[23] Alessandro Vespignani,et al. Epidemic dynamics and endemic states in complex networks. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.
[24] Dominik Wodarz,et al. Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. , 2003, Human gene therapy.
[25] Mark D. F. Shirley,et al. The impacts of network topology on disease spread , 2005 .
[26] Jean-Pierre Gabriel,et al. Stochastic Processes in Epidemic Theory , 1990 .
[27] Simon Wain-Hobson. Virus Dynamics: Mathematical Principles of Immunology and Virology , 2001, Nature Medicine.
[28] M. Vähä-Koskela,et al. Oncolytic viruses in cancer therapy , 2007, Cancer Letters.
[29] Jianjun Paul Tian,et al. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. , 2006, Cancer research.
[30] B. Fang,et al. Oncolytic virotherapy for cancer treatment: challenges and solutions , 2005, The journal of gene medicine.
[31] L. Ferrell,et al. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation , 2006, Cancer Gene Therapy.
[32] L. Meyers,et al. When individual behaviour matters: homogeneous and network models in epidemiology , 2007, Journal of The Royal Society Interface.
[33] F. Goodrum,et al. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle , 1997, Journal of virology.
[34] J. Kaplan,et al. Adenovirus-based cancer gene therapy. , 2005, Current gene therapy.
[35] Dominik Wodarz,et al. Computational approaches to study oncolytic virus therapy : insights and challenges , 2004 .
[36] D. Kirn,et al. Replicating viruses as selective cancer therapeutics. , 1996, Molecular medicine today.
[37] S. Hotte,et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. , 2003, Current opinion in molecular therapeutics.
[38] D. Kirn,et al. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. , 2007, Current cancer drug targets.
[39] D. Wodarz,et al. Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.